<DOC>
	<DOCNO>NCT02807896</DOCNO>
	<brief_summary>Multiple biomarker development validation useful marker generate next generation bio-data base genome research cohort study</brief_summary>
	<brief_title>Validation Useful Markers Generated Next Generation Bio-data Based Genome Research Cohort Study</brief_title>
	<detailed_description>1 . Objectives The study perform develop integrated analytical method genomic data clinical data bio-control network analysis , knowledge-based integrate analysis system develop biomarker early diagnosis treatment pancreatic cancer bile duct cancer , finally customize disease management system . Also , confirm effectiveness diagnostic chip research purpose apply pancreatic/bile duct cancer-specific biomarker , miRNA , find integrated analysis genomic data clinical data patient pancreatic/bile duct cancer blood patient pancreatic/bile duct cancer . 2 . Effective evaluation method The discrimination calibration algorithm diagnostic chip cancer type examine use 10-fold cross-validation ( 100 repetition ) . In 10-fold cross-validation , data randomly divide 10 size data , among 9 use make model train remain 1 applied test , process randomly independently repeat 100 time . The 10-fold cross-validated AUC calculate see discrimination diagnostic chip cancer type , 95 % confidence interval present non-parametric method . The 10-fold cross-validated calibration plot present see calibration diagnostic chip cancer type . The calibration plot visually demonstrate degree prediction compare prediction probability group ratio actual cancer patient list prediction probability order divide regular interval . Then , subject , AUC CA 19-9 , exist cancer diagnostic tool , calculate 95 % confidence interval present . To compare diagnostic chip cancer type AUC CA 19-9 , p-value calculate non-parametric method 10-fold cross-validated AUC .</detailed_description>
	<criteria>Patients histologically cytologically diagnose pancreatic cancer bile duct cancer Patient age : 20~80 year old Patients voluntarily determine participate clinical trial sign informed consent compliance Korean race Patients previous history chemotherapy radiation therapy pancreatic cancer and/or bile duct cancer Patients treatment surgery cancer organ within 5 year clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>biomarker</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>bile duct cancer</keyword>
	<keyword>miRNA</keyword>
</DOC>